OKONOGI TSUNEO

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…

Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…

Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…

Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…

Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…